Foghorn Therapeutics (FHTX) CFO resignation noted in Form 4

Foghorn Therapeutics Inc. (FHTX) disclosed that its Chief Financial Officer, Kristian F. Humer, has resigned from the company effective November 14, 2025.

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. (FHTX) disclosed that its Chief Financial Officer, Kristian F. Humer, has resigned from the company effective November 14, 2025. The filing notes that this Form 4 is being submitted solely as a voluntary exit filing, indicating that no further Section 16 ownership reports will be required from this individual. The document does not list any specific stock or option transactions, and focuses instead on formally recording the end of his reporting obligations as an officer of the company.

Insights

Corporate governance analyst

Formally records the CFO’s departure and end of insider reporting.

The filing states that Kristian F. Humer resigned as Chief Financial Officer of Foghorn Therapeutics Inc. effective November 14, 2025. It clarifies that this Form 4 serves as a voluntary exit filing, which is used when an insider is no longer subject to Section 16 reporting because they have left their officer or director role.

No equity transactions are listed in the non-derivative or derivative tables, so the document does not highlight any new stock or option activity tied to the resignation. The main functional impact is administrative: it confirms that Humer will no longer file ownership reports for FHTX under Section 16 going forward. Any broader implications of the CFO change would typically be described in a separate company disclosure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Foghorn Therapeutics (FHTX) report in this Form 4 filing?

The filing reports that Kristian F. Humer resigned as Chief Financial Officer of Foghorn Therapeutics Inc. (FHTX), effective November 14, 2025, and that this is a voluntary exit filing ending his Section 16 reporting obligations.

When did the Foghorn Therapeutics (FHTX) CFO resignation become effective?

The resignation of Kristian F. Humer as Chief Financial Officer of Foghorn Therapeutics Inc. became effective on November 14, 2025.

Does this FHTX Form 4 show any stock or option transactions?

No specific non-derivative or derivative security transactions are listed in the tables; the filing instead focuses on the CFO’s resignation and voluntary exit from Section 16 reporting.

What does a voluntary exit Form 4 mean for FHTX’s former CFO?

A voluntary exit Form 4 indicates that the former insider, here Kristian F. Humer, is no longer required to file Section 16 ownership reports for Foghorn Therapeutics Inc. (FHTX) because he has left his officer position.

What is the reporting person’s relationship to Foghorn Therapeutics (FHTX) in this Form 4?

The reporting person, Kristian F. Humer, is identified as an Officer of Foghorn Therapeutics Inc. with the title Chief Financial Officer, and the remarks section notes his resignation from that role effective November 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Humer Kristian

(Last) (First) (Middle)

500 TECHNOLOGY SQUARE

SUITE 700

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The Reporting Person resigned as Chief Financial Officer of Foghorn Therapeutics Inc., effective November 14, 2025. This Form 4 is being filed solely as a voluntary exit Form 4 indicating that no further reporting will be required of the Reporting Person.

	/s/ Michael LaCascia, Attorney-in-Fact for Kristian F. Humer	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.